FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths
Alarmed that an imbalance in deaths among patients taking a combination of Keytruda with Celgene’s Pomalyst and Revlimid could represent a threat in that whole …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.